TUESDAY, Dec. 14 (HealthDay News) -- The U.S. Food and Drug
Administration has approved a new once-daily dose for Prezista
(darunavir), combined with ritonavir to treat people infected with
HIV-1, a strain of the virus that causes AIDS.
In a news release, drug maker Tibotec Therapeutics said the
approval was meant for adults who hadn't shown resistance to
darunavir, the drug's active ingredient.
People with chronic liver disease including hepatitis or
cirrhosis should be carefully monitored while taking Prezista, the
company said. They also should be watched for signs of a severe
skin reaction, which could include severe rash accompanied by
fever, fatigue, muscle or joint pain, or blisters.
Prezista does not "cure" HIV-1 or AIDS, and will not prevent
transmitting the infection to others, the drug maker stressed.
To learn more about antiviral drugs used to treat HIV infection,